S

tung by reports of backpedaling on a pledge to limit drug price hikes, AbbVie (ABBV) insisted on Tuesday that it will stick to just one, single-digit price increase next year.

The statement came a day after news reports — including ours — indicated the drug maker would abandon its commitment to keep all price increases below 10 percent and raise prices only once a year, although AbbVie maintained its pledge referred only to this year. The original source for the stories was a report from a Wall Street securities analyst, who summarized AbbVie remarks following a meeting with company management last week.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.